When the fever will not stop, stop the pills!: a case report
Palavras-chave:
Neuroleptic malignant syndrome, Antipsychotic agents, Fever, Drug-related side effects and adverse reactions, Risk factors, Neuroleptics, Adverse drug reactions, Autonomic dysfunction, Factor, riskResumo
Neuroleptic malignant syndrome (NMS) is a neurologic emergency potentially fatal. This rare side effect is most commonly associated with first-generation antipsychotics and less frequently with atypical or second-generation antipsychotics. The diagnosis relies on both clinical and laboratory criteria, with other organic and psychiatric conditions being ruled out.
CASE REPORT: A 39-year-old female patient, who is institutionalized and completely dependent, has a medical history of recurrent urinary infections and colonization by carbapenem-resistant Klebsiella pneumoniae. Her regular medication regimen included sertraline, valproic acid, quetiapine, risperidone, lorazepam, diazepam, haloperidol, baclofen, and fentanyl. The patient began experiencing dyspnea. Upon physical examination, she exhibited hypotension and a diminished vesicular murmur at the right base during pulmonary auscultation. Initially, after hospitalization, she developed high febrile peaks associated with hemodynamic instability, prompting the initiation of antibiotic treatment. Despite this, her fever persisted without an increase in blood inflammatory parameters, and she developed purulent sputum, necessitating antibiotherapy escalation. The seventh day of hospitalization showed no improvement in
symptoms, suggesting NNMS as a differential diagnosis. All antipsychotic and sedative drugs, as well as antibiotherapy, were discontinued, after which the patient showed significant clinical improvement.
CONCLUSION: Antipsychotic agents are commonly employed to manage behavioral changes linked to various disorders. However, their severe side effects necessitate a high degree of vigilance, the cessation of all medications, and the implementation of supportive care measures. A prompt and accurate diagnosis of NMS is crucial to alleviating the severe, prolonged morbidity and potential mortality associated with this syndrome.
Downloads
Referências
Özdemir İ, Kuru E, Safak Y, Tulacı RG. A Neuroleptic Malignant Syndrome Without Rigidity. Psychiatry Investig. 2018;15(2):226-9. PMID: 29475219; https://doi.org/10.30773/pi.2017.06.05.
Mogollon Díaz JP, Lizcano Toloza LY, Serrano García AY, et al. Neuroleptic Malignant Syndrome Associated with Atypical Antipsychotics: A Case Report. Rev Colomb Psiquiatr. 2021:S0034-7450(21)00105-0. PMID: 34243899; https://doi.org/10.1016/j.rcp.2021.05.008.
Lao KSJ, Zhao J, Blais JE, et al. Antipsychotics and Risk of Neuroleptic Malignant Syndrome: A Population-Based Cohort and Case-Crossover Study. CNS Drugs. 2020;34(11):1165-75. PMID: 33010024; https://doi.org/10.1007/s40263-020-00767-9.
Schneider M, Regente J, Greiner T, et al. Neuroleptic Malignant Syndrome: Evaluation of Drug Safety Data from the AMSP Program During 19932015. Eur Arch Psychiatry Clin Neurosci. 2020;270(1):23-33. PMID: 30506147; https://doi.org/10.1007/s00406-018-0959-2.
Zaidi S, Irfan N, Khalid Z. Neuroleptic Malignant Syndrome with Normal Creatine Phosphokinase Levels: An Atypical Presentation. J Coll Physicians Surg Pak. 2022;32(4):S47-8. PMID: 35633010; https:// doi.org/10.29271/jcpsp.2022.Supp1.S47.
Velamoor R. Neuroleptic malignant syndrome: A Neuro-Psychiatric Emergency: Recognition, Prevention, and Management. Asian J Psychiatr. 2017;29:106-9. PMID: 29061403; https://doi.org/10.1016/j. ajp.2017.05.004.
El Khoury R, Kassab A, Dagher R, et al. Reconsidering Rigidity in the Diagnosis of Neuroleptic Malignant Syndrome: A Case Report. J Psychiatr Pract. 2020;26(4):320-3. PMID: 32692129; https://doi.org/10.1097/ PRA.0000000000000478.
Fervienza A, López-Baamonde M, Jacas A, et al. Neuroleptic Malignant Syndrome in a Postoperative Patient: A Case Report. Rev Esp Anestesiol Reanim. 2022;69(6):364-7. PMID: 35753931; https://doi.org/10.1016/j. redare.2022.06.004.
Knorr R, Schöllkopf J, Haen E. Das Maligne Neuroleptische Syndrom [Neuroleptic Malignant Syndrome]. Nervenarzt. 2018;89(3):300-10. PMID: 29209753; https://doi.org/10.1007/s00115-017-0463-3.
Guinart D, Misawa F, Rubio JM, et al. A Systematic Review and Pooled, Patient-Level Analysis of Predictors of Mortality in Neuroleptic Malignant Syndrome. Acta Psychiatr Scand. 2021;144(4):329-41. PMID: 34358327; https://doi.org/10.1111/acps.13359.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2025 São Paulo Medical Journal

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.